Corcept Therapeutics Slightly Up After FDA News (CORT)

Shares of Corcept Therapeutics Incorporated

are barely up, gaining 4 cents to $4.23, but had been as high as $4.68 earlier in the session on the back of seemingly positive FDA endpoint news

The company said that its drug Corlux, which is used for Cushing's Syndrome, is on track for FDA approval in the first quarter of 2011. Cushing's Syndrome is the overproduction of the hormone cortisol, or overexposure to cortisol. Its symptoms can include high blood sugar, high blood pressure, fatigue, and weak muscles. The FDA has already granted an orphan drug designation for Corlux for the treatment of Cushing's syndrome.